Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing...
United States Ian Stone Marcio Souza Exchange Commission Canale Communications Praxis Precision Medicines Inc
Source: marketscreener.com